Serial-solvent biomaterials are described. Embodiments include materials made in an organic solvent that are stripped of the solvent and used in a patient, where they imbibe water and form a hydrogel. These materials are useful for, among other things, delivering therapeutic agents, tissue augmentat
Serial-solvent biomaterials are described. Embodiments include materials made in an organic solvent that are stripped of the solvent and used in a patient, where they imbibe water and form a hydrogel. These materials are useful for, among other things, delivering therapeutic agents, tissue augmentation, and radiological marking.
대표청구항▼
1. A process of making a medical material comprising crosslinking a precursor to form an organogel around a powder of a water soluble biologic, with the organogel comprising, and the precursor being crosslinked in, an organic solvent selected from anhydrous and hydrophobic solvents, methylene chlori
1. A process of making a medical material comprising crosslinking a precursor to form an organogel around a powder of a water soluble biologic, with the organogel comprising, and the precursor being crosslinked in, an organic solvent selected from anhydrous and hydrophobic solvents, methylene chloride, or dimethyl carbonate, with the water soluble biologic being directly exposed to the organic solvent and the powder being dispersed in the organogel. 2. The process of claim 1 wherein the water soluble biologic is a protein that has a molecular mass of at least about 10,000 Daltons and a sugar is associated with the protein. 3. The process of claim 1 further comprising a second powder of a second water soluble biologic, with the powder and the second powder being dispersed in the organogel. 4. The process of claim 1 wherein the organogel is formed in an absence of aqueous solution. 5. The process of claim 1 further comprising removing the organic solvent from the organogel to thereby form a xerogel. 6. The process of claim 5 wherein the organic solvent is removed by a process chosen from the group consisting of vacuum removal, lyophilization, and freezing followed by application of a vacuum. 7. The process of claim 5 wherein the xerogel is a hydrogel upon exposure to an aqueous solution. 8. The process of claim 1, wherein the organogel comprises covalently crosslinked hydrophilic polymers. 9. The process of claim 1 wherein the organogel comprises ionically crosslinked polymers. 10. The process of claim 1 wherein the organogel comprises a member chosen from the group consisting of alginate, gellan, collagen, and polysaccharide. 11. The process of claim 1, wherein the precursor is covalently crosslinked to form the organogel. 12. The process of claim 11 wherein the precursor is reacted by free radical polymerization to form the organogel. 13. The process of claim 11 wherein the precursor is a first precursor comprising a first functional group and a second precursor comprising a second functional group, with the first functional group and the second functional group being reactive in the organic solvent to form the covalent crosslinks. 14. The process of claim 13 wherein the first functional group and the second functional group are each chosen from the group consisting of electrophile and nucleophile, and the reaction between the first functional group and second functional group is an electrophilic-nucleophilic reaction that forms the covalent crosslinks. 15. The process of claim 14 wherein the electrophilic group comprises succinimide, succinimide ester, n-hydroxysuccinimide, maleimide, succinate, nitrophenyl carbonate, aldehyde, vinylsulfone, azide, hydrazide, isocyanate, diisocyanate, tosyl, tresyl, or carbonyldiimidazole. 16. The process of claim 15 wherein the nucleophile group comprises a primary amine or a primary thiol. 17. The process of claim 13 wherein the first precursor and the second precursor are water soluble. 18. The process of claim 13 wherein at least one of the first precursor and the second precursor comprises a synthetic polymer. 19. The process of claim 18 wherein the first precursor comprises a polymer chosen from the group consisting of polyethylene glycol, polyacrylic acid, polyvinylpyrrolidone, and block copolymers thereof. 20. The process of claim 1 wherein the precursor is physically crosslinked to form the organogel. 21. The process of claim 1 comprising preparing the powder of the water soluble biologic according to a method that avoids denaturation of the biologic, and, once the powder has been prepared, preventing exposure of the powder to water until the medical material is used with a patient. 22. The process of claim 1 wherein the organic solvent is an anhydrous and hydrophobic solvent. 23. The process of claim 1 wherein the organic solvent is methylene chloride. 24. The process of claim 1 wherein the organic solvent is dimethyl carbonate. 25. The process of claim 1 wherein an amount of the water soluble biologic in the powder is at least 50% w/w. 26. The process of claim 1 wherein an amount of the water soluble biologic in the powder is at least 80% w/w. 27. The process of claim 1 wherein the powder consists essentially of the water soluble biologic. 28. The process of claim 1 wherein the water soluble biologic comprises a member of the group consisting of an antibody, an antibody fragment, and a short chain variable fragment antibody. 29. The process of claim 1 wherein the water soluble biologic comprises a protein or a fusion protein. 30. The process of claim 1 wherein the water soluble biologic comprises a member of the group consisting of a carbohydrate, a polysaccharide, a nucleic acid chain, an antisense nucleic acid, a ribonucleic acid (RNA), a deoxyribonucleic acid, a small interfering RNA, and an aptamer. 31. The process of claim 1 wherein the water soluble biologic comprises an anti-vascular endothelial growth factor (VEGF) agent. 32. The process of claim 1 wherein the water soluble biologic provides for treatment of macular degeneration. 33. The process of claim 1 wherein the water soluble biologic comprises an anti-cancer agent. 34. The process of claim 1 wherein the water soluble biologic comprises insulin. 35. The process of claim 1 wherein the water soluble biologic comprises a growth factor. 36. The process of claim 1 wherein the water soluble biologic comprises a member of the group consisting of antibiotics, antineoplastic agents, hormones, angiogenic agents, anti-angiogenic agents, neurotransmitters, psychoactive drugs, chemotherapeutic drugs, drugs affecting reproductive organs, and genes. 37. The process of claim 1 wherein the water soluble biologic is for treatment of a condition selected from the group consisting of elevated intraocular pressure, fungal blepharitis, conjunctivitis, keratitis, open-angle glaucoma, ocular hypertension, inflammation of an eye, keratoconjunctivitis, and allergic conjunctivitis. 38. A process of making a medical material comprising crosslinking a precursor to form an organogel around a powder of a water soluble biologic, with the organogel comprising, and the precursor being crosslinked in, an organic solvent selected from anhydrous and hydrophobic solvents, methylene chloride, or dimethyl carbonate, with the water soluble biologic being free of encapsulants other than the organogel and the powder being dispersed in the organogel,making a xerogel from the organogel,and providing the xerogel as a collection of particles, said collection being for delivery to a patient, wherein the xerogel is a hydrogel upon exposure to an aqueous solution. 39. The process of claim 38 wherein the organic solvent is an anhydrous and hydrophobic solvent. 40. The process of claim 38 wherein the organic solvent is methylene chloride. 41. The process of claim 38 wherein the organic solvent is dimethyl carbonate. 42. The process of claim 38 wherein an amount of the water soluble biologic in the powder is at least 50% w/w. 43. The process of claim 38 wherein an amount of the water soluble biologic in the powder is at least 80% w/w. 44. The process of claim 38 wherein the powder consists essentially of the water soluble biologic. 45. The process of claim 38 wherein the water soluble biologic comprises a member of the group consisting of an antibody, an antibody fragment, and a short chain variable fragment antibody. 46. The process of claim 38 wherein the water soluble biologic comprises a protein or a fusion protein. 47. The process of claim 38 wherein the water soluble biologic comprises a member of the group consisting of a carbohydrate, a polysaccharide, a nucleic acid chain, an antisense nucleic acid, a ribonucleic acid (RNA), a deoxyribonucleic acid, a small interfering RNA, and an aptamer. 48. The process of claim 38 wherein the water soluble biologic comprises an anti-vascular endothelial growth factor (VEGF) agent. 49. The process of claim 38 wherein the water soluble biologic provides for treatment of macular degeneration. 50. The process of claim 38 wherein the water soluble biologic comprises an anti-cancer agent. 51. The process of claim 38 wherein the water soluble biologic comprises insulin. 52. The process of claim 38 wherein the water soluble biologic comprises a growth factor. 53. The process of claim 38 wherein the water soluble biologic comprises a member of the group consisting of antibiotics, antineoplastic agents, hormones, angiogenic agents, anti-angiogenic agents, neurotransmitters, psychoactive drugs, chemotherapeutic drugs, drugs affecting reproductive organs, and genes. 54. The process of claim 38 wherein the water soluble biologic is for treatment of a condition selected from the group consisting of elevated intraocular pressure, fungal blepharitis, conjunctivitis, keratitis, open-angle glaucoma, ocular hypertension, inflammation of an eye, keratoconjunctivitis, and allergic conjunctivitis.
Polson Alan M. (Fort Collins CO) Swanbom Deryl D. (Fort Collins CO) Dunn Richard L. (Fort Collins CO) Cox Charles P. (Fort Collins CO) Norton Richard L. (Fort Collins CO) Lowe Bryan K. (Fort Collins , Apparatus for forming a biodegradable implant precursor.
Pathak Chandrashekhar P. (Waltham MA) Sawhney Amarpreet S. (Newton MA) Hubbell Jeffrey A. (Concord MA) Herman Stephen J. (Andover MA) Roth Laurence A. (Windham NH) Campbell Patrick K. (Georgetown MA), Apparatus for intraluminal photothermoforming.
Rhee Woonza M. ; Rao Prema R. ; Chu George H. ; DeLustro Frank A. ; Harner Carol F. H. ; Sakai Naomi ; Schroeder Jacqueline A., Biocompatible adhesive compositions.
Rhee Woonza M. ; Rao Prema R. ; Chu George H. ; DeLustro Frank A. ; Harner Carol F. H. ; Sakai Naomi ; Schroeder Jacqueline A., Biocompatible adhesive compositions.
Dunn Richard L. (451 Boardwalk Dr. RLD ; Apt. 501 Fort Collins CO 80526) English James P. (2500 Melinda Cir. Birmingham AL 35214) Cowsar Donald R. (4657 Round Forest Dr. Birmingham AL 35213) Vanderbi, Biodegradable in-situ forming implants and methods of producing the same.
Dunn Richard L. (Fort Collins CO) English James P. (Birmingham AL) Cowsar Donald R. (Birmingham AL) Vanderbilt David D. (Birmingham AL), Biodegradable in-situ forming implants and methods of producing the same.
Hubbell Jeffrey A.,CHX ; Kieras Mark T. ; Ron Eyal S. ; Rowe Stephen C., Biodegradable macromers for the controlled release of biologically active substances.
Silver Frederick A. (Long Valley NJ) Berg Richard A. (Lambertville NJ) Birk David E. (Somerset NJ) Weadock Kevin (Piscataway NJ) Whyne Conrad (Somerset NJ), Biodegradable matrix and methods for producing same.
Silver Frederick H. (Long Valley NJ) Berg Richard A. (Lambertville NJ) Doillon Charles J. (Edison NJ) Weadock Kevin (Piscataway NJ) Whyne Conrad (Edgewood MD), Biodegradable matrix and methods for producing same.
Dunn Richard L. (Fort Collins CO) Tipton Arthur J. (Fort Collins CO) Southard George L. (Fort Collins CO) Rogers Jack A. (Fort Collins CO), Biodegradable polymer composition.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Biologically inert, biocompatible-polymer conjugates.
Schwartz Herbert E. ; Blackmore John M., Bioresorbable compositions of carboxypolysaccharide polyether intermacromolecular complexes and methods for their use in reducing surgical adhesions.
Rhee Woonza M. (Palo Alto CA) Rao Prema R. (Los Gatos CA) Chu George H. (Cupertino CA) DeLustro Frank A. (Belmont CA), Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications.
Rhee Woonza M. (Palo Alto CA) Rao Prema R. (Los Gatos CA) Chu George H. (Cupertino CA) DeLustro Frank A. (Belmont CA) Harner Carol F. H. (Redwood Shores CA) Sakai Naomi (San Mateo CA) Schroeder Jacqu, Collagen-based bioadhesive compositions.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Collagen-polymer conjugates.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Collagen-polymer conjugates.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Collagen-polymer conjugates.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Collagen-polymer conjugates.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Collagen-polymer conjugates containing an ether linkage.
Ahola,Manja; S채ilynoja,Eija; Salonen,Jukka; Penttinen,Risto; Yli Urpo,Antti, Compositions for controlled release of a biologically active agent, and the preparation thereof.
Hubbell, Jeffrey A.; Elbert, Donald; Schoenmakers, Ronald, Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds.
McAnalley Bill H. (Grand Prairie TX) Boyd Stephen (Tyler TX) Carpenter Robert H. (Bastrop TX) Hall John E. (Grand Prairie TX) St. John Judith (Irving TX), Dried hydrogel from hydrophilic-hygroscopic polymer.
Ding Shulin ; Olejnik Orest ; Reis Brenda L., Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers.
Hubbell Jeffrey A. (Austin TX) Pathak Chandrashekhar P. (Waltham MA) Sawhney Amarpreet S. (Newton MA) Desai Neil P. (Los Angeles CA) Hill-West Jennifer L. (Austin TX) Hossainy Syed F. A. (Austin TX), Gels for encapsulation of biological materials.
Hubbell Jeffrey A. (Concord MA) Pathak Chandrashekhar P. (Austin TX) Sawhney Amarpreet S. (Newton MA) Desai Neil P. (Los Angeles CA) Hossainy Syed F. A. (Austin TX), Gels for encapsulation of biological materials.
Hubbell Jeffrey A. ; Pathak Chandrashekhar P. ; Sawhney Amarpreet S. ; Desai Neil P. ; Hill Jennifer L. ; Hossainy Syed F. A., Gels for encapsulation of biological materials.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Implants coated with collagen-polymer conjugates.
Melanson David A. ; Sawhney Amarpreet S. ; Levine Marc Alan ; Spiridigliozzi John C. ; Bromander Thomas S., Initiator priming for improved adherence of gels to substrates.
Oppenheim ; Richard Charles ; Marty ; Jennifer Joy ; Speiser ; Peter, Injectable compositions, nanoparticles useful therein, and process of manufacturing same.
Tice Thomas R. (Birmingham AL) Lewis Danny H. (Gardendale AL) Cowsar Donald R. (Birmingham AL) Beck Lee R. (Birmingham AL), Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents.
Harris J. Milton (Huntsville AL), Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for m.
Ronan John M. ; Thompson Samuel A., Medical devices comprising ionically and non-ionically crosslinked polymer hydrogels having improved mechanical properties.
Peyman Gholam A. (123 Walnut St. New Orleans LA 70118), Method and apparatus for controlled release drug delivery to the cornea and anterior chamber of the eye.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Method of augmenting tissue using collagen-polymer conjugates.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Method of augmenting tissue with collagen-polymer conjugates.
Nesburn Anthony B. (Malibu CA) Gorin Michael (Rockville MD) Martinez Marvin (Glendale CA) Kenney M. Cristina (Malibu CA) Maguen Ezra (Los Angeles CA), Method of crosslinking amino acid containing polymers using photoactivatable chemical crosslinkers.
Tsuei Alexander C. (Woodbury MN) Kogl ; III Lorenz (Stillwater MN) Pendergrass ; Jr. Daniel B. (Mendota Heights MN), Method of encapsulation and microcapsules produced thereby.
Rhee Woonza M. (Palo Alto CA) Berg Richard A. (Los Altos CA) Rosenblatt Joel S. (Palo Alto CA) Tefft Jacqueline A. (Redwood City CA) Braga Larry J. (Fremont CA) Smestad Thomas L. (Palo Alto CA), Method of preparing crosslinked biomaterial compositions for use in tissue augmentation.
Rhee Woonza M. (Palo Alto CA) Berg Richard A. (Los Altos CA) Rosenblatt Joel S. (Palo Alto CA) Tefft Jacqueline A. (Redwood City CA) Braga Larry J. (Fremont CA) Smestad Thomas L. (Palo Alto CA), Method of preparing crosslinked biomaterial compositions for use in tissue augmentation.
Rhee Woonza M. ; Rao Prema R. ; Chu George H. ; DeLustro Frank A. ; Harner Carol F. H. ; Sakai Naomi ; Schroeder Jacqueline A., Method of preventing formation of adhesions following surgery.
Pathak Chandrashekhar P. ; Sawhney Amarpreet S. ; Hubbell Jeffrey A. ; Herman Stephen J. ; Roth Laurence A. ; Campbell Patrick K. ; Berrigan Kevin M. ; Jarrett Peter K. ; Coury Arthur J., Methods for intraluminal photothermoforming.
Fogarty Thomas J. ; Freislinger Kirsten ; Weinberg Steven ; Cox Brian J. ; Evans Michael A. ; Kim Steven W. ; Lenker Jay A., Modular intraluminal prostheses construction and methods.
Harris J. Milton ; Veronese Francesco Maria,ITX ; Caliceti Paolo,ITX ; Schiavon Oddone,ITX, Multiarmed, monofunctional, polymer for coupling to molecules and surfaces.
Hubbell Jeffrey A. (Austin TX) Elbert Donald (Austin TX) Hill-West Jennifer L. (Austin TX) Drumheller Paul D. (Austin TX) Chowdhury Sanghamitra (Round Rock TX) Sawhney Amarpreet (Newton MA), Multifunctional organic polymers.
Hubbell Jeffrey A. ; Elbert Donald ; Hill-West Jennifer L. ; Drumheller Paul D. ; Chowdhury Sanghamitra ; Sawhney Amarpreet S., Multifunctional organic polymers.
Hughes, Patrick M.; Boix, Michele; Sarrazin, Christian; Do, Marina, Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods.
Barclay Brian L. ; Childers Jerry D. ; Wright Jeri ; Place Virgil A. ; Wong Patrick S.-L., Oral osmotic device for delivery of nystatin with hydrogel driving member.
Erlebacher Jay (55 Woodland Park Dr. Tenafly NJ 07670) Goldweit Richard S. (82 Park St. Tenafly NJ 07670), Percutaneous arterial puncture seal device and insertion tool therefore.
Wong Sui-Ming ; Cooper Eugene R. ; Xu Shuqian, Pharmaceutical compositions containing polyalkylene block copolymers which gel at physiological temperature.
Hubbell Jeffrey A. (Austin TX) Pathak Chandrashekhar P. (Waltham MA) Sawhney Amarpreet S. (Newton MA) Desai Neil P. (Los Angeles CA) Hill Jennifer L. (Austin TX), Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Polymer conjugates ophthalmic devices comprising collagen-polymer conjugates.
Sawhney Amarpreet S. ; Enscore David J. ; Goodrich Stephen D. ; Nason William C. ; Yao Fei ; Weaver Douglas ; Jarrett Peter K. ; Coury Arthur J. ; Rudowsky Ronald S. ; Powell Michelle D. ; Avila Luis, Polymerizable biodegradable polymers including carbonate or dioxanone linkages.
Cohn Daniel (Jerusalem ILX) Yitzchaiek Shlomo (Ramat Gan ILX) Bilenkis Sophie (Jerusalem ILX), Polyurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same.
Ramstack J. Michael (Lebanon OH) Herbert Paul F. (Wayland MA) Strobel Jan (Westchester OH) Atkins Thomas J. (Cincinnati OH), Preparation of biodegradable microparticles containing a biologically active agent.
Rhee Woonza M. (Palo Alto CA) Berg Richard A. (Los Altos CA) Rosenblatt Joel S. (Palo Alto CA) Schroeder Jacqueline A. (Redwood City CA) Braga Larry J. (Fremont CA) Smestad Thomas L. (Palo Alto CA) F, Process for preparing a sterile, dry crosslinking agent.
Chesterfield Michael P. (Norwalk CT) Muth Ross R. (Brookfield CT) Kennedy John (Stratford CT), Process for preparing particles of bioabsorbable polymer.
Pietsch Hanns (Hamburg DEX) Hohmann Volker (Norderstedt DEX) Eckloff Willi (Hamburg DEX), Process for the preparation of a powder mixture for surgical use.
Vanderhoff, John W.; Lu, Cheng Xun; Lee, Clarence C.; Tsai, Chi-Chun, Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained.
Wallace Donald G. ; Cruise Gregory M. ; Rhee Woonza M. ; Schroeder Jacqueline Anne ; Coker ; III George T. ; Maroney Marcee M., Rapid gelling biocompatible polymer composition.
Wallace, Donald G.; Cruise, Gregory M.; Rhee, Woonza M.; Schroeder, Jacqueline Anne; Coker, III, George T.; Maroney, Marcee M.; Trollsas, Olof Mikael, Rapid-gelling biocompatible polymer composition and associated methods of preparation and use.
Sawhney Amarpreet S. ; Melanson David A. ; Pathak Chandrashekar P. ; Hubbell Jeffrey A. ; Avila Luis Z. ; Kieras Mark T. ; Goodrich Stephen D. ; Barman Shikha P. ; Coury Arthur J. ; Rudowsky Ronald S, Redox and photoinitiator priming for improved adherence of gels to substrates.
Sawhney Amarpreet S. ; Melanson David A. ; Pathak Chandrashekar P. ; Hubbell Jeffrey A. ; Avila Luis Z. ; Kieras Mark T. ; Goodrich Stephen D. ; Barman Shikha P. ; Coury Arthur J. ; Rudowsky Ronald S, Redox and photoinitiator systems for priming and improved adherence of gels to substrates.
Bito Laszlo Z. (New York NY) Stjernschantz Johan W. (Uppsala SEX), Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.